Results 61 to 70 of about 94,605 (281)
By profiling the spatiotemporal hepatic landscape of CHB mouse models, the originally peri‐portal localized KCs migrated to the peri‐central in a CXCL9‐CXCR3‐dependent manner, facilitating their interaction with HBV+ hepatocytes. The interaction promoted LMD in KCs through ASGR1‐induced LXRα degradation, which, in turn, induced CSC formation via Stat3 ...
Jingqi Shi +18 more
wiley +1 more source
ABSTRACT The cytosine (C) modifications 5‐methylcytosine (mC) and 5‐hydroxymethylcytosine (hmC) are central regulatory elements of mammalian genomes. Both marks occur in double‐stranded DNA in either strand‐symmetric or ‐asymmetric fashion, but it is still poorly understood how this symmetry information is selectively read out by the nuclear proteome ...
Lena Engelhard +8 more
wiley +1 more source
Recent approvals of oligonucleotide analogue drugs to alter gene expression have been welcomed by patient communities but not universally supported. These compounds represent a class of drugs that are designed to target a specific gene transcript, and ...
Ianthe Pitout +3 more
doaj +1 more source
ERM Inhibition Confers Ferroptosis Resistance through ROS‐Induced NRF2 Signaling
ERM inhibition disrupts ERM‐actin interactions, elevating ROS and triggering KEAP1 degradation, which stabilizes and activates NRF2. Nuclear NRF2 induces cytoprotective genes, notably HMOX1, enhancing redox buffering and suppressing lipid peroxidation to resist erastin‐induced ferroptosis.
Menghao Qiao +19 more
wiley +1 more source
Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease
Neuromuscular disorders such as Duchenne Muscular Dystrophy and Spinal Muscular Atrophy are neurodegenerative genetic diseases characterized primarily by muscle weakness and wasting.
Valentina Sardone +4 more
doaj +1 more source
ALS antisense oligonucleotides [PDF]
Isis and three academic groups are developing antisense oligonucleotide therapeutics for the most common cause of ALS. The drugs target hexanucleotide repeat expansions in C9orf72 and mitigate neurotoxicity in vitro. Animal models are not yet available.
openaire +1 more source
Functional, Pharmacogenomic, and Immune Landscapes of Long Non‐Coding RNAs in Cancer
A systematic analysis of 33 cancer types reveals widespread associations between lncRNAs and cancer pathways, drug responses, immune features, and immunotherapy outcomes. The study identifies key lncRNAs linked to therapeutic response and adverse events and introduces PILNC, an interactive web portal for exploring the functional, pharmacogenomic, and ...
Runhao Wang +15 more
wiley +1 more source
Unnatural Amino Acid and Emerging Chemistry Approaches to Map RNA–Protein Interactions
This review highlights emerging chemistries for mapping RNA–protein interactions, including genetically encoded unnatural amino acids, novel photocrosslinkers, and non‐photoactivatable crosslinking systems. We compare their mechanisms, reactivity and applications, outlining how these next‐generation tools enable higher‐resolution, site‐specific ...
Eryn Lundrigan +3 more
wiley +2 more sources
Pharmacokinetics of antisense oligonucleotide drugs
This review covers the pharmacokinetic characteristics of the various antisense oligonucleotide drugs. A comparison of the pharmacokinetics of drugs first and second generation.
M. R. Khaitov, V. V. Smirnov
doaj
5.8S ribosomal RNA plays an important role in protein synthesis and eukaryotic ribosome translocation. Contact DNA insecticides based on antisense fragments of 5.8S ribosomal RNA gene of gypsy moth Lymantria dispar L.
Volodymyr V. Oberemok +9 more
doaj +1 more source

